Unveiling the Protective Power of NAD+ Against Alzheimers Disease This article explains how NAD+ helps maintain neuronal function by improving mitochondrial efficiency and activating sirtuins for cellular repair
GLP-1 is produced in the nucleus of the solitary tract in the brainstem, which projects to numerous areas of the CNS expressing the GLP-1 receptor (GLP-1R), such as the hypothalamus (Dickson et al., 2012)
Never inject same spot twice in a row
Key Findings from a Large-Scale Study A large real-world study using the TriNetX Analytics Network (20102022) analyzed outcomes in 5,291 PV patients treated with GLP-1 RAs compared with 79,027 untreated patients
Real-world studies have confirmed these results: a 2025 study published in Diabetes, Obesity and Metabolism found tirzepatide was associated with greater weight loss over 6 months than semaglutide in patients without diabetes, consistent with the trial data
Summary In summary, GLP-1 RA based therapies are being rigorously studied in management of MASLD in particular more advanced stages and likely will become foundational therapies in the future
.png)
